Phenylpropylaminopentane

(-)-1-Phenyl-2-propylaminopentane (also known as (-)-PPAP and N,α-dipropylphenethylamine)  is a stimulant of the substituted phenethylamine class that has been derived from selegiline. When compared with selegiline and other substituted phenethylamines (-)-PPAP has a notably different mechanism of action and pharmacological effect.

(-)-PPAP is classified as a monoaminergic activity enhancer that stimulates the impulse propagation mediated transmitter release of the neurotransmitters dopamine, norepinephrine and serotonin in the brain. Unlike stimulants such as amphetamine, which release a flood of monoamine neurotransmitters in an uncontrolled manner, (-)-PPAP instead only increases the amount of neurotransmitters that get released when a neuron is stimulated by receiving an impulse from a neighbouring neuron. Both amphetamine and (-)-PPAP promote the release of monoamines and deuteramines, however while amphetamine causes neurons to release neurotransmitter stores into the synapse regardless of external input, (-)-PPAP does not influence the pattern of neurotransmitter release and instead releases a larger amount of neurotransmitters than normal.

(-)-PPAP has no monoamine oxidase inhibitory activity.

Pre-clinical research
The therapeutic index for PPAP in animal models is greater than that of amphetamine while producing comparable improvements in learning, retention, and antidepressant effects in animal models. It has been proposed as a potential therapeutic for ADHD, Alzheimer's disease, and depression based on preclinical findings.